



NEWS RELEASE

Attorney General Mike Hilgers

FOR IMMEDIATE RELEASE

July 15, 2026

Attorney General Hilgers Announces \$29.6 Million Settlement with Glenmark over Conspiracy to Inflate Prices and Limit Competition

If You Bought Certain Generic Prescription Drugs in the United States Between May 1, 2009, and December 31, 2019, You Could be Eligible for Money

Lincoln - Attorney General Hilgers joined a coalition of 48 states and territories today announcing a \$29.6 million settlement with Glenmark to resolve allegations that the generic drug manufacturer engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. As part of the settlement agreement, Glenmark will cooperate in the ongoing multistate litigations against 33 corporate defendants and 25 individual executives. The company has further agreed to a series of internal reforms to ensure fair competition and compliance with antitrust laws.

Nebraska's share of today's settlement is \$128,191.77.

The Glenmark settlement follows settlements with Lannett, Bausch, Apotex, and Heritage, totaling \$66.95 million.

This latest settlement comes as the States prepare for the first trial to be held in Hartford, Connecticut, and is anticipated to be scheduled in late 2026.

If you purchased a generic prescription drug manufactured by either Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com or visit www.AGGenericDrugs.com.

The cases all stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives that met with each other during industry dinners, "girls nights out," lunches, cocktail parties, golf outings, and communicated via frequent

telephone calls, emails, and text messages that sowed the seeds for their illegal agreements. Throughout the complaints, defendants use terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to describe how they unlawfully discouraged competition, raised prices, and enforced an ingrained culture of collusion. Among the records obtained by the States is a two-volume notebook containing the contemporaneous notes of one of the States' cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.

States and territories settling today with Glenmark include: Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and Puerto Rico.

###

Suzanne Gage
Director of Communications
Nebraska Attorney General's Office
Office: 402-471-2656
Mobile: 402-560-3518
Suzanne.gage@nebraska.gov